Bristol-Myers Squibb Company BMY

PRINCETON, N.J., September 30, 2026--U.S. FDA Approves Expanded Indication for BMS’s CAMZYOS for the Treatment of Symptomatic oHCM in Adults and Pediatric Patients

Investors seeking a high yield and stable fundamentals in the healthcare sector need look no further than Bristol Myers Squibb.

A spokesperson confirmed that a “limited number” of liver-related safety events, including a patient death, were observed in testing of Bristol Myers’ admilparant — though it’s unclear whether the drug was to blame.

Fortune today announced an additional group of speakers for the Fortune 500 Innovation Forum, November 16–17, 2026, in Detroit, Michigan. The newly confirmed leaders will join CEOs, entrepreneurs, policymakers, investors, and civic innovators from across the country for conversations about the forces reshaping American business, technology, work, manufacturing, and prosperity.

Bristol Myers Squibb has raised its dividend for 17 straight years, but a looming patent cliff on its biggest cash generator puts that streak on a collision course with reality in 2027.

Key TakeawaysPfizer yields about 6% and Bristol Myers about 4%, and each has more than $22 billion of revenue from drugs losing U. S.

Pfizer's shares cost more than Johnson & Johnson's for each dollar of reported profit, even after factoring in a loss quarter over the past year. Investors usually pay more for growth, yet Pfizer (PFE) had the weakest sales growth of the six companies in its peer group. Are you overpaying for Pfizer stock versus its rivals.

Merck (MRK) stock returned 96% in the past twelve months, against 16.8% for the S&P 500. With the shares 4.0% below their 52-week high, you need a reason Merck can keep growing. In its fiscal Q2 2026 call, management looked past its best-selling drug to newer ones. So what is Merck stock's biggest opportunity from here.

The global CAR T-cell therapy market is projected to grow from USD 7.24 billion in 2026 to USD 13.78 billion by 2031, registering a 13.7% CAGR. Growth is driven by rising cancer prevalence, technological advances, expanding clinical trials, and increased investment, while high costs and adverse effects remain barriers. Yescarta led the product market in 2025, hospitals were the largest end-user segment, and Asia Pacific is forecast to record the fastest growth through 2031.Dublin, Sept. 30, 2026

In September 2026, Bristol Myers Squibb reported first-time, pivotal Phase 3 EXCALIBER-RRMM data showing ZENBEXUS (iberdomide) plus daratumumab and dexamethasone produced a statistically significant, clinically meaningful improvement in minimal residual disease–negative complete responses versus a standard daratumumab-based regimen in relapsed or refractory multiple myeloma. This MRD-focused outcome is particularly important because it informs the accelerated approval pathway for ZENBEXUS...

Summit Therapeutics stock jumped Tuesday after AstraZeneca made a $2 billion investment in the smaller biotech.

Bristol-Myers Squibb (NYSE:BMY) reported pivotal Phase 3 EXCALIBER-RRMM data for ZENBEXUS in relapsed or refractory multiple myeloma. The Phase 3 trial showed a clinically meaningful advantage in MRD-negative complete response rates versus standard therapy. The first full readout of EXCALIBER-RRMM highlights potential clinical and commercial relevance for ZENBEXUS in a crowded myeloma treatment field. The MRD-negative complete response results from EXCALIBER-RRMM are important, but investors...

The deal would give AstraZeneca exposure to a promising cancer treatment without acquiring the company outright.

Bristol-Myers Squibb has delivered a 51.6% gain over the past year, helped by fresh drug data and a steadily expanding pipeline, which puts fresh focus on what investors are really paying for its future cash flows today. With the stock recently closing at US$63.88, the key issue is whether that price still lines up with what the company’s current and prospective cash generation can support. Bristol-Myers Squibb’s 51.6% one year return puts meaningful expectations into the share price, so the...

A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.